REFERENCES
- Dupont AG and Helier F: Generics and cost-effective prescri-bing in BeEgium — does bioequiva[ence abivays transEate in the-rapeutic equ iva Fence? Acta Clin. Belg 2009; 5:406–414.
- Helier FR and Dupont AG: Generics — need for clinicaE concern? Acta Clin. Belg 2009; 5:415–422.
- Buxton ILO: Pharmacokinetics and pharmacodynamics — the dynamics of drug absorption, distribution, action and elimina-tion. In "Goodman & Gkman's The PharmacoEogicaE Basis of Therapeutics" (e[eventh edition), Brunton LL, Lazo JS and Parker KL (eds.), McGraw-HiR, New York, pp. 1–39, 2006.
- Hauschke D, Steinijans V and Pigeot I: Bioequiva[ence Studies in Drug Deve[opment — Methods and Applications, John Wkey & Sons Ltd. (UK), 2007.
- Benet LZ: Understanding bioequiva[ence testing. Transplant. Proc. 31 (SuppE 3A): 7S-9S, 1999.
- Dhanaraj M and Jayaveki A: Non-equiva[ence of bioavakabkity between generic and branded form of sodium vaEproate. Neu-rol. India 52: 398, 2005 (Letter to the Editor).
- PasquaEotto AC and Denning DW: Generic substitution of itra-conazo[e resuking in subtherapeutic Fevek and resistance. Int. J. Antimicrob. Agents 30: 93–94, 2007 (Letter to the Editor).
- Hoharitanon S, ChaichaEotornkuE J and Sindhupak W: a com-parison of the efficacy between two itraconazo[e generic pro-ducts and the innovative itraconazo[e in the treatment of tinea pedis. J. Med. Assoc. Thai 88 (SuppE 4): S167-S172, 2005.
- KesseEheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK and Shrank WH: CEinicaE equiva[ence of generic Med. Assoc. 300: 2514–2526, 2008.
- Niazi SK: Handbook of Bioequivalence Testing, "Drugs and the Pharmaceutical Sciences", vol. 171, Informa Healthcare (Ney
- EMEA Note for Guidance on the Investigation of Bioavailability and Bioequivalence. CPMP/EWP/QWP/1401/98, London, 26
- EMEA Guideline on the Investigation of Bioequivalence, CPMP/ EWP/QWP/1401/98, London, 24 July 2008 (draft).
- Williams RL: Therapeutic equivalence of generic drugs – Response to National Association of Boards of Pharmacy, Center for Drug Evaluation and Research, FDA, 1997 ( www.fda.gov/cder/news.ntiletter.htm).
- Health Canada Guidance for Industry: Bioequivalence require-ments — critical dose drugs. Health Products and Food Branch, Health Canada, Ottawa, 2006.
- McLaughlin DB: generic drug use in epilepsy. Neurol. Asia 12 (Suppl. 1): 25–26, 2007.
- Blossom DB et al.: Outbreak of adverse reactions associated with contaminated heparin. N. Eng.]. Med. 359: 2674–2684, 2008.